title: Levamisole and low-dose prednisolone in the treatment of   reccurent aphthous stomatitis.
abstract: BACKGROUND
  Recurrent aphthous stomatitis (RAS) is the most common oral mucosal disease. However, the available therapies for RAS only relieve symptoms and do not provide a cure.
  
  
  OBJECTIVE
  This study assessed the response to treatment with levamisole and low-dose prednisolone drug combination in patients with RAS.
  
  
  METHODS
  Fifty RAS subjects were enrolled in the single-blind randomized placebo-controlled trial. Study medications were administered thrice daily for 3 consecutive days/week for 3 consecutive weeks. Patients in Group 1 received placebo, Group 2 received levamisole (50 mg) and Group 3 received levamisole (50 mg) and low-dose prednisolone (5 mg). Patients were followed up for 60 days after treatment. Response to treatment was assessed using the following clinical parameters: pain due to ulcers, number of ulcers/episode, size of ulcers, duration of ulcers, and frequency of ulcers (episodes/month).
  
  
  METHODS
  Mann–Whitney U-test.
  
  
  RESULTS
  A statistically significant improvement was noted in all parameters except for the size of ulcers in patients treated with levamisole alone and with combination of levamisole and low-dose prednisolone. There was no statistically significant improvement in the placebo group. Both active groups had significantly better improvement when compared to placebo group, while there was no significant difference between the two active groups.
  
  
  CONCLUSIONS
  Levamisole alone and combination of levamisole and low-dose prednisolone are effective modes of therapy for RAS.
authors.forename: Neelkamal
authors.initials: N
authors.lastname: Sharda
authors.forename: M C
authors.initials: MC
authors.lastname: Shashikanth
authors.forename: Priyanka
authors.initials: P
authors.lastname: Kant
authors.forename: Manika
authors.initials: M
authors.lastname: Jain
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007978:Levamisole / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010919:Placebos; D011239:Prednisolone / Q000008:administration & dosage*; D012008:Recurrence; D016037:Single-Blind Method; D013281:Stomatitis, Aphthous / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D010919:Placebos; D007978:Levamisole; D011239:Prednisolone